As global markets experience a rally with the S&P 500 and Nasdaq Composite reaching all-time highs, investors are closely watching inflationary trends and economic indicators that suggest a mixed outlook. In this environment, dividend stocks can offer a compelling opportunity for those seeking income stability, as they provide regular payouts that can help offset market volatility.
| Yamato Kogyo (TSE:5444) | 4.43% | ★★★★★★ |
| Nissan Chemical (TSE:4021) | 4.07% | ★★★★★★ |
| NCD (TSE:4783) | 4.21% | ★★★★★★ |
| Japan Excellent (TSE:8987) | 4.31% | ★★★★★★ |
| Guangxi LiuYao Group (SHSE:603368) | 4.41% | ★★★★★★ |
| GakkyushaLtd (TSE:9769) | 4.64% | ★★★★★★ |
| E J Holdings (TSE:2153) | 5.42% | ★★★★★★ |
| Daito Trust ConstructionLtd (TSE:1878) | 4.38% | ★★★★★★ |
| Banque Cantonale Vaudoise (SWX:BCVN) | 4.72% | ★★★★★★ |
| Allianz (XTRA:ALV) | 4.52% | ★★★★★★ |
Click here to see the full list of 1544 stocks from our Top Global Dividend Stocks screener.
Let's review some notable picks from our screened stocks.
★★★★★☆
Bros Eastern., Ltd is involved in the research, development, production, and sale of dyed mélange and color-spun yarns with a market capitalization of CN¥7.11 billion.
Bros Eastern., Ltd generates its revenue primarily from the research, development, production, and sale of dyed mélange and color-spun yarns.
5%
Bros Eastern Ltd's dividend payments are covered by earnings and cash flows, with payout ratios of 76.4% and 84.5%, respectively. Despite a high dividend yield in the top 25% of the CN market, its dividends have been unstable over the past decade, showing volatility and unreliability. Recent earnings reports indicate net income growth to CNY 173.47 million for Q1 2025, although annual figures showed a decline compared to the previous year.
★★★★☆☆
Tibet Weixinkang Medicine Co., Ltd. focuses on the research, development, production, and sale of chemical drugs and their bulk drugs in China, with a market cap of CN¥4.53 billion.
Tibet Weixinkang Medicine Co., Ltd. generates its revenue primarily from the pharmaceutical industry, amounting to CN¥1.28 billion.
Dividend Yield: 3.1%
Tibet Weixinkang Medicine's dividends are supported by earnings and cash flows, with payout ratios of 62.3% and 64.3%, respectively, placing its yield in the top 25% of CN market payers. However, its dividend history is marked by volatility over seven years, indicating unreliability despite recent growth in payments. The company's Q1 2025 earnings showed a decline with net income at CNY 84.54 million compared to CNY 94.91 million a year earlier.
